<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0004416'>Premature atherosclerosis</z:hpo> (ATS) in SLE patients is an important clinical problem </plain></SENT>
<SENT sid="1" pm="."><plain>It is explained not only by excess of traditional risk factors, but also by specific factors linked to disease activity and therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Such specific factors include the following: antioxLDL and anti CRP antibodies, immune complexes, <z:chebi fb="0" ids="37684">mannose</z:chebi>-binding lectin, disturbances of metabolism of annexin A5, <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, immunologically determined <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, influence of medication </plain></SENT>
<SENT sid="3" pm="."><plain>As a conclusion,<z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> in SLE patients results from an interplay between traditional and nontraditional risk factors </plain></SENT>
<SENT sid="4" pm="."><plain>Therapeutic influences suggest antiatherogenic effects for hydroxychloroquine and <z:chebi fb="1" ids="35705">immunosuppressants</z:chebi> and a doubtful proatherogenic influence of <z:chebi fb="11" ids="16962">cortisone</z:chebi> </plain></SENT>
</text></document>